Camurus AB (SE:CAMX)
:CAMX
Want to see SE:CAMX full AI Analyst Report?
CAMX Stock Chart & Stats
kr665.00
-kr17.00(-2.71%)
At close: 4:00 PM EST
kr665.00
-kr17.00(-2.71%)
Day’s Range― - ―
52-Week Rangekr430.80 - kr754.50
Previous CloseN/A
Volume19.01K
Average Volume (3M)126.83K
Market Cap
kr31.58B
Enterprise Valuekr27.57B
Total Cash (Recent Filing)kr3.88B
Total Debt (Recent Filing)kr110.08M
Price to Earnings (P/E)45.9
Beta0.81
Next Earnings
Jul 15, 2026EPS Estimate
3.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.49
Shares Outstanding59,989,185
10 Day Avg. Volume148,560
30 Day Avg. Volume126,834
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)8.62
Price to Sales (P/S)16.11
P/FCF Ratio49.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr700.00Price Target Upside5.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)13.47
Revenue Forecast (FY)kr2.74B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsCamurus has sustained very high gross margins and strong operating and net margins since 2022. Durable margin structure—driven by proprietary long‑acting formulations, royalty streams and limited COGS—supports robust cash generation and reinvestment capacity over the next 2–6 months.
Conservative Balance Sheet And LiquidityLow leverage and growing equity/assets provide financial flexibility for product launches and R&D spending. A conservative capital structure reduces refinancing risk and supports execution on U.S. expansion and milestone capture without immediate funding strain.
Regulatory And Launch CatalystsRegulatory progress and recent approvals create durable commercial inflection points: a U.S. PDUFA decision and EU/UK launches expand addressable markets, underpinning multi‑quarter revenue upside if approvals/rollouts proceed and reimbursement pathways are secured.
Bears Say
Revenue Growth VolatilityRevenue has swung materially over recent years with TTM decline versus prior period, reducing visibility on sustainable top‑line momentum. For a specialty pharma reliant on product adoption, uneven sales and milestone timing complicate medium‑term planning and forecasting.
Market Access And Reimbursement ConstraintsStructural reimbursement, funding and provider remuneration barriers in major European markets limit near‑term uptake for the core Buvidal franchise. Persistent access constraints cap addressable market and can materially slow revenue conversion despite clinical need.
Planned OpEx Increases For U.S. Launch And R&DMaterial planned increases in commercial and R&D spending will pressure margins until U.S. launches and pipeline readouts deliver sales or milestones. Execution risk is elevated: higher OpEx requires successful commercialization or milestone realization to justify the longer‑term return on investment.
Camurus AB News
CAMX FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr430.80 and its highest was kr754.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr31.58B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Jul 15, 2026 which is in 44 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on May 12, 2026. The company reported kr2.4 earnings per share for the quarter, missing the consensus estimate of kr3.471 by -kr1.071.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 3.83.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,989,185 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr2.4 in its last earnings report, missing expectations of kr3.471. Following the earnings report the stock price went down -8.807%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in SE:CAMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
CAMX Company Deck
CAMX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive strategic and financial picture for Camurus: full-year revenue and operating profitability improved materially, net cash increased significantly, regulatory approvals and U.S. FDA acceptance (PDUFA set) support upcoming launches, Brixadi royalties showed strong growth, and early-stage R&D (CAM2056) delivered compelling data. At the same time, the company faces notable short-term headwinds: Q4 revenue and product sales were down due to a U.K. distribution change and FX effects, quarter operating profit contracted, access/reimbursement barriers in several large European markets constrain Buvidal upside, and timing uncertainty remains for the SORENTO readout and some milestone revenues. Management provided constructive 2026 guidance while flagging planned increases in OpEx tied to U.S. launch preparation. Overall, strengths in commercial traction, cash position, approvals, and pipeline momentum outweigh the near-term operational and market-access challenges.View all SE:CAMX earnings summariesCAMX Stock 12 Month Forecast
Average Price Target
kr700.00
▲(5.26% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Options Prices
Currently, No data available
---